Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
News Release Digital Asset Direct

Cloudrise Is Taking 2022 By Storm

Cloudrise

Cloudrise Inc., a technology-enabled services firm focused on data protection, cloud security, and privacy, continues to make waves with a flurry of exciting news to kick-off 2022. Cloudrise is pleased to announce the acquisition of CyberOrchard, an information security managed service organization located in the United Kingdom. Cloudrise CEO, Rob Eggebrecht, shared his thoughts: “The merger of the two companies brings a breadth of knowledge and expertise to Cloudrise, paving the way to expand our portfolio of data protection services to the global market.” As part of the acquisition, Jason Bird, CyberOrchard’s Founder and CEO, has been named Chief Technology Officer (CTO) at Cloudrise. Bird has over 25 years of experience in cybersecurity, managed services, data governance, and privacy. “Data protection is becoming more complex every day, and at Cloudrise we believe collaboration is the path to better protection for our customers. We are partnering with the strongest data-centric technology companies to bring innovative solutions to our customers, such as Netskope, AWS, Digital Guardian, Microsoft, OneTrust, Varonis, BigID, and Veritas, just to name a few,” said Bird. This news comes just a week after Netskope named Cloudrise as their Global Services Partner of the Year. “This achievement illustrates Cloudrise’s commitment to delivering innovative service offerings to customers worldwide,” said Joe Infantino, Chief Operating Officer at Cloudrise. Additionally, Cloudrise is pleased to announce that CRN®, a brand of The Channel Company, has named Cloudrise to its Managed Service Provider (MSP) 500 list in the Managed Security 100 category for 2022. Winners are recognized for helping end users increase efficiency, simplify solutions, and maximize their return on investment. Cloudrise is taking 2022 by storm and encourages its followers to stay tuned for future announcements. About Cloudrise Cloudrise is a technology-enabled services firm, specializing in delivering data-centric services customized to meet organizations’ business needs. Drawing from 20+ years of experience in the field, they have tailored their services to be focused on securing organizations’ data wherever it resides. Cloudrise knows how to identify gaps, build and optimize controls and integrations across the enterprise, and deploy data-centric technologies across multiple industries, geographies and organizational sizes – all with the expertise to navigate an ever-changing data compliance and regulatory landscape. Cloudrise can be found at Cloudrise.com or on LinkedIn. About CyberOrchard UK-based CyberOrchard is an information security managed services organization, home to experts with over 20 years of data security experience. Whether the risk to organizations' data lives in transit on the network, at rest in storage, or in use at an endpoint, CyberOrchard provides the necessary data security bundled service offerings, consultancy and managed services to significantly reduce organizations' risk of data loss. CyberOrchard can be found at cyberorchard.com or on LinkedIn. Contact Details Jodi Lewis +1 800-917-7619 sales@cloudrise.com Company Website https://cloudrise.com/

April 06, 2022 07:00 AM Mountain Daylight Time

Green Cubes Technology Announces Membership in CircuBAT Research Program

Green Cubes Technology

Green Cubes Technology, a leader in electrification and Lithium power solutions, today announced its participation as a founding member in CircuBAT. CircuBAT is a Swiss research program that aims to create a Swiss circular business model for the production, application, and recycling of Lithium-ion batteries. Seven Swiss research institutions and 24 companies are joining forces to look for ways to boost sustainability in all stages of a battery’s life cycle. CircuBAT will focus on finding solutions that boost sustainability in all phases of a Lithium-ion battery’s life cycle. This will include extending the lifespan of batteries during their first application. Researchers hope to achieve this by developing optimal charging and discharging strategies as well as new concepts for battery construction that make repairs easy. The project also aims to put batteries to use as stationary energy storage systems after they are retired from their first mobility-related application. To that end, CircuBAT will look at the best ways of integrating these batteries at a local level and ensuring their safe and efficient operation. Finally, the researchers will look for solutions for remanufacturing batteries and recovering materials that enable large quantities of high-quality secondary raw materials to be used to produce new batteries. Bern University of Applied Sciences BFH is the Leading House in the CircuBAT project. On the science side, an additional six Swiss research institutions are involved in the project: Empa, the Swiss Center for Electronics and Microtechnology (CSEM), the University of St. Gallen (HSG), the Eastern Switzerland University of Applied Sciences (OST), the Switzerland Innovation Park Biel / Bienne (SIPBB) and the EPFL (Swiss Federal Institute of Technology). These institutions are joined by 24 companies from economy and industry, among them Kyburz, Leclanché, Bühler and Green Cubes Technology. As a founding member of CircuBAT, Green Cubes Technology has made a multi-year financial investment in the program. The company will also contribute first-use lithium-ion batteries for experimentation and testing within the program, provide engineering design services to develop new more-efficient batteries, and contribute intellectual property to achieve the objectives of CircuBAT. Green Cubes Technology will participate in two working groups. The “First Use” group will focus on extending the life of first-use batteries through extensive analysis of deployed batteries in the field. Green Cubes Technology will contribute performance data collected from its prolific installed base of Lithium-ion batteries. The “Second Life” group will focus on creating second-use and second-life opportunities to minimize the total CO 2 footprint of lithium-ion battery systems during their lifetime. Since its inception 30 years ago, Green Cubes Technology has gained considerable experience minimizing the environmental impact of its deployed batteries. This positive impact will be amplified with a system of second life batteries, where the installed base of first use batteries is redeployed when they reach a certain age limit. The Lithium-ion cells used in Green Cubes Technology’s batteries are non-toxic, and are currently recycled and reprocessed at their end of life. Going forward, these cells can be repurposed into less demanding second life applications such as backup energy storage. “We joined the CircuBAT research program because its mission is very well aligned with ours,” said Keith Washington, CEO of Green Cubes Technology. “We all want the same thing and that is a circular economy for Lithium-ion batteries. We are looking forward to sharing our experience, and giving electric mobility batteries a second life with our Swiss partners in the CircuBAT research program, as they strive to make the Swiss economy as sustainable as possible” More information on the research program can be found on its website: https://circubat.ch. About Green Cubes Technology Green Cubes Technology develops and manufactures safe and reliable electrification solutions that enable its OEM and enterprise customers to transition from Lead Acid and Internal Combustion Engine (ICE) power to Lithium-ion battery power. Green Cubes utilizes proven hardware and software platforms to build the most reliable Lithium power solutions in its industries. With over 300 employees across six countries, Green Cubes has been producing innovative, high-performance and high-quality power solutions since 1986. More information can be found at https://greencubestech.com. Contact Details Ray Young (General Media, Investor Relations) +1 916-505-4245 ray@razorsharppr.com Hayley Luz (Trade Media) +1 425-918-2742 hluz@greencubestech.com Company Website https://greencubestech.com/

March 31, 2022 10:00 AM Eastern Daylight Time

CORRECTING and REPLACING G Medical Innovations takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity

G Medical Innovations Holdings

This release issued on March 30, 2022 is being replaced with the following corrected version due to multiple revisions. The updated release reads: G Medical Innovations (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity Poised for expansion and growth, the company continues to process thousands of COVID-19 PCR and rapid antigen/flu testing; and its personal healthcare monitoring business expects sales growth G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) takes aggressive approach to protect shareholders by combatting naked shorting of GMVD shares with an investigation to end the criminal activity and ensure perpetrators will face aggressive legal action in the interest of protecting shareholders. G Medical Innovations Holdings Ltd. (NASDAQ: GMVD) announced that it has investigated aggressive naked short sales of its stock and is confident that it has identified the perpetrators of this illegal activity. The company will defend its shareholders by taking all regulatory and legal action against this criminal activity. It has instructed its legal department to contact the SEC, FINRA, and NASDAQ to conduct full investigations on their ends. G Medical continues to demonstrate growth and commitment to expansion across its business units. Its wholly owned subsidiary, G Medical Tests and Services, Inc. as well as G-Medical Lab Services Inc., continues to process thousands of COVID-19 PCR and rapid antigen/flu tests from its sites and its personal healthcare monitoring business expects sales growth via negotiations with major health systems and is prepared for increased testing capacity, given new virus variants expected to emerge. In addition, G Medical Innovations is involved in negotiations with numerous hospitals and healthcare systems for sales of its Prizma Care remote patient monitoring devices and services. Patients, cardiologists, and health providers across the country rely on G Medical’s innovative Prizma monitoring devices and services for accurate and reliable remote monitoring. The company is planning a shareholder’s conference call soon. At that time, it will report on achievements during Q1 2022. About G Medical Innovations G Medical Innovations Holdings Ltd. is an early commercial-stage healthcare company engaged in the development of next-generation mHealth and telemedicine solutions and monitoring service platforms. The Company’s solutions and services can empower consumers, patients, and providers to better monitor, manage and improve clinical and personal health outcomes, especially for those who suffer from cardiovascular disease (or CVD), pulmonary disease, and diabetes. The Company’s current product lines consist of its Prizma medical device (or Prizma), a clinical-grade device that can transform almost any smartphone into a medical monitoring device, enabling both healthcare providers and individuals to monitor, manage and share a wide range of vital signs and biometric indicators; its Extended Holter Patch System, a multi-channel patient-worn biosensor that captures electrocardiography (or ECG) data continuously, including its QT Syndrome Prolongation Detection Capabilities Patch. In addition, the Company is developing its Wireless Vital Signs Monitoring System (or VSMS), which is expected to provide full, continuous, and real-time monitoring of a wide range of vital signs and biometrics. Its monitoring services include provision of Independent Diagnostic Testing Facility (or IDTF) monitoring services and private monitoring services. Visit https://gmedinnovations.com/. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, G Medical is using forward-looking statements when it discusses that it continues to process thousands of COVID-19 PCR and rapid antigen/flu tests from its sites and is prepared for increased testing capacity, given new virus variants expected to emerge. Because such statements deal with future events and are based on G Medical’s and McDade Products’ current expectations, they are subject to various risks and uncertainties, and actual results, performance, or achievements of G Medical and McDade Products could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading “Risk Factors” in G Medical’s prospectus filed pursuant to Rule 424(b)(4), filed with the Securities and Exchange Commission (“SEC”) on June 28, 2021, the registration statement on Form F-1 filed on February 14, 2022 (registration no. 333-262724) and in any subsequent filings with the SEC. Except as otherwise required by law, the companies undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. G Medical and McDade Products are not responsible for the contents of third-party websites. Contact Details Kobi Ben-Efraim, CFO +972 8-958-4777 service@gmedinnovations.com Company Website https://gmedinnovations.com/

March 30, 2022 12:26 PM Eastern Daylight Time

Modivcare Awarded ISO 27001 Security Certification

Modivcare

Modivcare Inc. (“Modivcare”) (Nasdaq: MODV), a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions focused on improving patient outcomes, today announced it has been awarded ISO 27001 certification for its non-emergency medical transportation division. ISO 27001 is an international information security management standard published by the International Organization for Standardization (ISO) – the world's largest developer of voluntary international standards – and the International Electrotechnical Commission (IEC). Unlike other certifications and compliance attestations that are much narrower in scope, ISO 27001 is a broad-spectrum certification that speaks to the health and robustness of an organization’s overall information security program. ISO 27001 sets out requirements for Modivcare’s information security management system to ensure the protection of sensitive data. The certification confirms that Modivcare operates a fundamentally sound, risk-focused professional security program based on an open security standard that has been tested for decades. Adhering to this standard enables Modivcare to manage the security of assets such as financial information, intellectual property, employee details, or information entrusted by third parties. “A company’s information security program sets the foundation for its ability to provide secure solutions, such as defending against and recovery from cyberattacks or preventing the loss of sensitive data,” said Modivcare Chief Information Officer, Walt Meffert. “This certification is significant because it tells our patients and customers that they can be confident their data is secure within our environment.” Modivcare’s non-emergency medical transportation (NEMT) services provide patients access to safe and reliable rides to health services. Working with local, community-based transportation providers, Modivcare is the largest broker of NEMT in the nation and brings more than 35 years of experience to its transportation providers and more than 75 million trips managed annually for 30 million patients across the United States. About Modivcare Modivcare Inc. (“Modivcare”) (Nasdaq: MODV) is a technology-enabled healthcare services company that provides a platform of integrated supportive care solutions for public and private payors and their patients. Our value-based solutions address the social determinants of health (SDoH), enable greater access to care, reduce costs, and improve outcomes. We are a leading provider of non-emergency medical transportation (NEMT), personal and home care, remote patient monitoring, medication management and meal delivery. Modivcare also holds a minority equity interest in CCHN Group Holdings, Inc. and its subsidiaries (“Matrix Medical Network”), which partners with leading health plans and providers nationally, delivering a broad array of assessment and care management services to individuals that improve health outcomes and health plan financial performance. To learn more about Modivcare, please visit www.modivcare.com. Contact Details Media Kate Zerone, Director, Ombudsman & Communications kate.zerone@modivcare.com Amendola Communications Kim Warth kwarth@acmarketingpr.com

March 30, 2022 09:30 AM Eastern Daylight Time

AngelEye Health Strengthens Senior Sales Team with Series of Strategic New Hires

AngelEye Health

AngelEye Health, a leading provider of family engagement solutions for hospital neonatal and pediatric intensive care units, today announced a move to expand its sales network with the addition of five account managers and one clinical sales associate, creating the company’s first internal sales team. Kent Meeks, Arturo Ruvalcaba, David Broad, Scott Duyck, Vicki Koch and Olivia McCracken each bring extensive healthcare industry experience having served in similar roles representing Natus NicView, Medela, and GE. Kent Meeks: (Account Manager for the Southeast). Previously served as a product sales specialist for Maternal-Infant Care at GE Healthcare. Arturo Ruvalcaba: (Account Manager, Texas, Oklahoma, Kanas, Missouri). As a territory manager at Medela, Arturo spent eight years focused squarely on product sales in support of the NICU environment. David Broad: (Account Manager for the Northeast). When a product specialist at Natus Medical Incorporated, David spearheaded NicView streaming camera system sales throughout the eastern half of the US. Scott Duyck: (Account Manager for the West coast). Scott has worked in neonatal product sales for over 12 years, first at Natus Medical, selling products including hearing screening products, phototherapy lights, and brain monitors and at Medela selling feeding-related solutions. Vicki Koch: (Account Manager for the Midwest). Formerly a Midwest regional sales manager at Medela, Vicki brings to the position a deep appreciation for the care and compassion found in the NICU and a deep knowledge for complex hospital selling. Olivia McCracken: (Clinical Sales Associate, Florida). Olivia is a Registered Nurse with extensive experience working in the NICU and conducting clinical research. This new investment in the AngelEye Health sales team comes as the organization looks to grow its health system relationships and arm more hospital partners with innovative family engagement solutions. Today, AngelEye’s platform hosts four solutions each designed to elevate the parent/patient experience. The platform includes: The company's innovative CameraSystem™ which brings live-streaming video of the patient to family members anywhere, anytime, on any device. OnlineEducation™, a parental portal where hospitals can upload customizable education resources and monitor parents' progress on the patient's path to discharge. PatientConnect™, providing a secure one-way communication channel from the care team to family to easily share patient status and memorable moments. MilkTracker, an end-to-end feeding and milk inventory management solution. In 2022, AngelEye Health intends to continue to strengthen efforts to bring on more hospital partners that already have engagement solutions in place and are aware of the benefits of integrating tele-engagement capabilities into the NICU, but that are looking for a more comprehensive technology offering coupled with an exceptional level of customer service. "This is an exciting time for AngelEye Health as we look to strategically grow our hospital and health system relationships, and as such, extend our ability to have an even greater impact on the patients/families and care teams who rely on our solutions to enhance communication and care collaboration in NICUs and pediatric units," said Christopher Rand, CEO of Angel Eye Health. "With these recent account manager appointments, we are reinforcing our commitment to building the right team with the right level of healthcare industry experiences to help make our aggressive growth goals a reality in 2022." About AngelEye Health AngelEye Health has a deep understanding of the value that both family engagement and family-centered care bring to the neonatal and pediatric intensive care environment. We provide a complete HIPAA-compliant tele-engagement platform to integrate parents simply and seamlessly into the child's care team. Our approach has a proven, positive impact on the quality of the family experience, care delivery workflows for the dedicated bedside team, and patient outcomes. From admission to discharge, AngelEye positively impacts staff, families, and patients along the journey and ultimately to a successful transition home. From bonding, patient progress and treatment communication, feeding, and focused education, AngelEye offers a portfolio of solutions for supporting the highly specialized needs of the NICU and PICU today and of the future. www.angeleyehealth.com Contact Details Jessy Green +1 917-689-9295 jessy.green@svmpr.com Company Website https://www.angeleyehealth.com/

March 29, 2022 10:00 AM Eastern Daylight Time

UNOS Receives Over $800,000 in Grant to Support Organ Tracking Tech

United Network for Organ Sharing

S.L. Gimbel Foundation, a component fund at the Inland Empire Community Foundation, recently awarded United Network for Organ Sharing (UNOS) an $836,208 grant to support two innovative tools: the UNOS Organ Tracking Service and the UNOS Travel App. UNOS is the engine that powers the national organ donation and transplantation system. “UNOS continues to harness the power of modern technology and meaningful collaborations to ensure that lifesaving donor organs continue to get where they need to go,” UNOS CEO Brian Shepard said. “Both the tracking service and the travel app are the most recent examples of how we’re working to provide donor families, recipient families, patients and medical professionals with the peace of mind they need, and I am proud that our team continues to develop evidence-based, tech-driven solutions that save even more lives.” "The S.L. Gimbel Foundation Fund is proud to support the important work of UNOS and the innovative tools they're using to help organ donors and recipients across the country," said Celia Cudiamat, SVP of Grants and Community Impact at IECF. "It is a great privilege to disperse these funds on their behalf, knowing their desire to focus on human dignity issues as a priority in their giving." UNOS Organ Tracking Service Developed by UNOS and tested by organ procurement organizations (OPOs) across the country, the service is now in use by 13 of the nation’s 57 OPOs. With this service, OPOs and transplant hospitals know when an organ is in transit, when it arrives at an airport, when the flight departs, and when the organ has arrived at its destination, all in real time. The grant will fund the continued expansion of the tracking service, providing upgraded technology, a suite of advanced notifications including travel predictions, and other improvements. This will provide OPOs with an even more reliable, user-friendly way to track organs in transit. UNOS Travel App Select OPOs began piloting the UNOS Travel App in late 2020. The tool helps OPOs make more informed transportation plans by providing them with a view of all available options, including flight schedules, driving directions, travel times and other useful information. The grant will pave the way for the full deployment of the UNOS Travel App, making it possible to integrate this service into the current organ offer system, assisting both OPOs and transplant hospitals with logistical decisions. This generous grant comes after a year of historic firsts for UNOS and the entire donation and transplant community, including surpassing 41,000 transplants in a single year for the first time in 2021, as well as record-breaking numbers of kidney, heart, and liver transplants. ### About United Network for Organ Sharing United Network for Organ Sharing (UNOS) is the mission-driven non-profit serving as the nation’s transplant system under contract with the federal government. We lead the network of transplant hospitals, organ procurement organizations, and thousands of volunteers who are dedicated to honoring the gifts of life entrusted to us and to making lifesaving transplants possible for patients in need. Working together, we leverage data and advances in science and technology to continuously strengthen the system, increase the number of organs recovered and the number of transplants performed, and ensure patients across the nation have equitable access to transplant.. About the Inland Empire Community Foundation Founded in 1941, the Inland Empire Community Foundation is the oldest and largest community foundation in Inland Southern California. We partner with individuals, families and corporations to help them achieve their charitable goals. Since inception, we have given out over $124 million in grants and scholarships. For more information visit the IECF’s website at www.iegives.org. Be a part of our conversation on Facebook, Twitter and LinkedIn. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 25, 2022 04:06 PM Eastern Daylight Time

AngelEye Health Obtains ISO 9001:2015 Certification for Quality Management

AngelEye Health

AngelEye Health, a leading provider of family engagement solutions for hospital neonatal and pediatric intensive care units, today announced that it has maintained the ISO 9001:2015 Certification for Quality Management Systems (QMS). This continued validation helps cement its reputation as a quality-first organization, generating additional credibility with hospital partners around the country. ISO 9001:2015 is a globally recognized quality standard developed and published by the International Organization for Standardization (ISO). Organizations globally use the standard to demonstrate to their customers that they can provide consistent products and services. The standard is based on several quality management principles, including AngelEye’s strong customer focus, the involvement of the organizations' upper management and leadership structures, an outlined, process-based approach, and ongoing improvement of the quality management system. To earn the ISO 9001:2015-certification, AngelEye underwent and passed a rigorous third-party audit. As a family engagement solutions provider, this accreditation demonstrates that management has done its due diligence in continuously providing products and services that meet customer and applicable statutory and regulatory requirements. The company’s ISO 9001:2015 certificate was issued by DEKRA, an organization globally renowned for over a century in the testing, inspection, and certification of quality management standards. "The ISO QMS certification provides the industry with an objective standard on the definition of quality. We are so proud that the AngelEye Health name will now be synonymous with consistency in products and services that not only meet but exceed what our hospital partners are looking for in a family engagement solution provider,” said David Landman AngelEye Health’s chief commercial officer. “As a customer focused organization, we are always looking for ways to better support our current and future clients. We believe that this ISO 9001:2015 certification will go a long way to support our team’s efforts to continuously improve our approach to quality management.” About AngelEye Health AngelEye Health has a deep understanding of the value that both family engagement and family-centered care bring to the neonatal and pediatric intensive care environment. We provide a complete HIPAA-compliant tele-engagement platform to integrate parents simply and seamlessly into the child's care team. Our approach has a proven, positive impact on the quality of the family experience, care delivery workflows for the dedicated bedside team, and patient outcomes. From admission to discharge, AngelEye positively impacts staff, families, and patients along the journey and ultimately to a successful transition home. From bonding, patient progress and treatment communication, feeding, and focused education, AngelEye offers a portfolio of solutions for supporting the highly specialized needs of the NICU and PICU today and of the future. www.angeleye.health Contact Details SVM PR & Marketing Jessy Green +1 917-689-9295 jessy.green@svmpr.com Company Website https://angeleye.health/

March 24, 2022 10:00 AM Eastern Daylight Time

VinFuture foundation announces 2022 VinFuture webinar series for nominators

Vingroup

HANOI, VIETNAM – Media OutReach – 24 March 2022 - As part of the sequence of activities for the second VinFuture Prize season, VinFuture Foundation has officially launched a series of six webinars in six different time zones around the world. This series of events aims to provide information directly to scientists across the globe and attract the most outstanding nominations to promote post-COVID-19 reconstruction and sustainable development. The webinar series will take place via Zoom from March 23 to April 19, 2022 and will be tailored for distinct geographic regions and time zones, including: US East and West Coasts, Europe, Africa, Asia, and Oceania. The webinars will be led by members of the VinFuture Prize Council and Pre-screening Committee and will feature the prize laureates from the first season. The second VinFuture Prize season, themed "Reshaping and Reviving", is focused on inventions and scientific initiatives accelerating the world's reconstruction and sustainable development following the COVID-19 pandemic. Since its official launch on February 16, 2022, the second season has received immense support from the global scientific community, with more than 1,000 organizations and individuals from 81 countries participating as nominators for the prize. To date, the scientific community in Asia has contributed the highest number of nominators with 34% of the total share, followed closely by the Americas with 33%, Europe with 22%, Australia with 6%, and Africa with 5%. The webinar series aims to provide the latest information directly to scientists worldwide and promote diversity and breadth in all potential areas. Through this series, VinFuture will address inquiries and concerns about the nomination process as well as share practical and inspirational perspectives from members of the Pre-screening Committee, the Prize Council, and especially the first season’s laureates. VinFuture Prize is an annual international award for breakthrough scientific and technological inventions that have created, or have the potential to create, meaningful changes in people's lives. Despite being a new award, with the mission of serving humanity and a selection process with high integrity and transparency, VinFuture has already built a strong reputation in the global scientific community. In the first season, VinFuture received nearly 1,200 nomination submissions from six continents around the world just four months after officially launching the nomination portal. VinFuture's nominators include institutes of higher education such as Harvard University, Cambridge University, Oxford University, and University of Tokyo, and prestigious organizations such as the National Institutes of Health of the United States, The Max Planck Society of Germany, Chinese Academy of Sciences, and more. The laureates of the first VinFuture Prize season are truly outstanding scientists that have been honored worldwide for their scientific achievements for humanity. The Grand Prize, with a value of US$3 million, was awarded to three prominent scientists: Dr. Katalin Karikó, Prof. Drew Weissman (USA) and Prof. Pieter Cullis (Canada) for the development of mRNA technology, paving the way for the production of effective vaccines to help prevent COVID-19 outbreaks, as well as potential vaccines for HIV, cancer, autoimmune and genetic diseases, helping to protect the future health of millions of people in the world. 2022 nomination portal: https://online.vinfutureprize.org/nomination For more details about the Prize: Detailed instructions about the nomination process and nomination form: https://online.vinfutureprize.org/nomination FAQs: https://vinfutureprize.org/faqs/ Information about the first VinFuture Prize: https://vinfutureprize.org/laureates/ * Webinar Series Agenda: About the VinFuture Foundation The VinFuture Foundation, established on December 20th, 2020, on the occasion of International Human Solidarity Day, is an independent, not-for-profit foundation established by billionaire Mr. Phạm Nhật Vượng, and his wife, Madam Phạm Thu Hương. The vision and mission of the Foundation is to create positive changes in the lives of millions of people in the world. The core activity of the Foundation is awarding the annual VinFuture Prizes to breakthrough scientific research and technological innovations that have already contributed or have the potential to contribute to the betterment of life for people. The VinFuture Prize consists of four prize categories, of which the Grand Prize – with a value of US$3 million – is one of the largest annual global prizes, and three additional Special Prizes, worth US$500,000 each, are dedicated to Female Innovator(s), Innovator(s) from Developing Country(ies), and Innovator(s) with Outstanding Achievements in Emerging Fields. In addition, the Foundation also conducts many activities to realize its mission, such as funding research, collaborating in academic development, and promoting STEM education. 2021 VinFuture Prize Laureates The Grand Prize: Dr. Katalin Karikó, Prof. Drew Weissman (USA) and Prof. Pieter Cullis (Canada) with their breakthrough research on mRNA technology for vaccines. Special Prize for “Innovators with Outstanding Achievements in Emerging Fields”: Professor Omar Yaghi (USA) with his work on discovering metal-organic frameworks (MOFs)' Special Prize for “Female Innovators”: Professor Zhenan Bao (USA) with her work on developing flexible electronics with the sensing properties of human skin. Special Prize for “Innovators from Developing Countries”: Prof. Salim S. Abdool Karim and Professor Quarraisha Abdool Karim (South Africa), for their Research on Pre-Exposure Prophylaxis with Antibiotics virus. Contact Details Vingroup v.nammh@vingroup.net Company Website https://vinfutureprize.org/

March 24, 2022 09:30 AM Eastern Daylight Time

Image

Lawsuit Challenging Nation’s Kidney Allocation Policy Is Dismissed

United Network for Organ Sharing

A lawsuit against United Network for Organ Sharing (UNOS) and the U.S. Department of Health and Human Services (HHS) challenging the nation’s current kidney allocation policy was dismissed on March 22 when plaintiffs withdrew their challenge, according to the District Court for the Southern District of Iowa. This follows a ruling in November of 2021 when the 8 th Circuit Court of Appeals ruled that the same plaintiffs were not likely to win on the merits of the case they presented. The kidney policy went into effect in March of last year. “The current kidney allocation policy is the result of respectful debate and discussion that included voices from across the donation and transplantation community,” said UNOS CEO Brian Shepard. “The numbers show that this policy is working as intended, and we thank our many dedicated OPTN volunteers, who donated their time to make our high-performing system even better.” Recent data shows kidney transplants for all populations have increased following the implementation of the policy, including a 22% increase in kidney transplants nationwide. UNOS will continue to monitor key metrics of the policy's performance to ensure that it continues as expected and to identify any areas for further development. “These numbers not only prove that the policy is increasing equity, but that the process that got us here was both effective and fair,” said UNOS Board President Matthew Cooper, M.D. “As we see the policy’s very real impact on the lives of kidney waitlist candidates and recipients, all of the patients, donor families, volunteers and others involved in developing this policy should be proud of what they have accomplished.” About UNOS United Network for Organ Sharing (UNOS) is a non-profit, charitable organization that serves as the Organ Procurement and Transplantation Network (OPTN) under contract with the federal government. The OPTN helps create and define organ allocation and distribution policies that make the best use of donated organs. This process involves continuously evaluating new advances and discoveries so policies can be adapted to best serve patients waiting for transplants. All transplant programs and organ procurement organizations throughout the country are OPTN members and are obligated to follow the policies the OPTN creates for allocating organs. Contact Details Anne Paschke +1 804-782-4730 anne.paschke@unos.org Company Website https://unos.org

March 23, 2022 06:20 PM Eastern Daylight Time

1 ... 187 188 189 190 191 ... 260